White Guide and Orange Guide Formatting Project - Pfizer

More documents

Recommendations

Info

Orange Guide – Chapter 4: Federal Employee Interactions and Lobbying What is Lobbying? ........................................................................................................................................................ 17 Reporting Lobbying Time and Expense...................................................................................................................... 19 Gifts to Government Officials ............................................................................................................................ 20 Gifts to Public Employees .................................................................................................................................. 20 State-Specific Laws ...................................................................................................................................................... 21 States’ General Lobbying Disclosure Laws ........................................................................................................ 21 States’ Lobbying Laws Impacting Marketing ................................................................................................... 22 State Formularies ................................................................................................................................................ 23 Campaign Contributions .............................................................................................................................................. 23 The Pfizer Political Action Committee ....................................................................................................................... 24 FOR MORE INFORMATION ....................................................................................................................................... 24 72 Rev. 09/12 Page 2 of 25
Orange Guide – Chapter 4: Federal Employee Interactions and Lobbying Chapter 4: FEDERAL EMPLOYEE INTERACTIONS AND LOBBYING Introduction This Chapter focuses on: (a) the important rules you must understand and follow when engaging in promotional and non-promotional activities with the Department of Veterans Affairs (VA), Department of Defense (DoD) and other federal employees; and (b) summarizes certain key Pfizer policies regarding lobbying registration and disclosure. This Chapter is relevant to any colleague who interacts with healthcare professionals (HCP) employed by the federal government (including interactions with any HCP employed by the VA or DoD) or engages in lobbying activities with any elected or appointed state or federal government official or public employee (including state Medicaid agency employees and public hospital and government HCPs). Each Colleague is responsible for adhering to Pfizer's policies regarding interactions with federal employees and lobbying activities involving federal or state government officials and public employees. Non-compliance with these policies puts the Company at risk and can subject Colleagues to disciplinary action up to and including termination. Federal Employee Interactions As Pfizer’s sales to the federal government continue to increase, interactions with government officials (e.g., Director of Medicaid) and government employees (e.g., a physician at a federal institution or at a federal prison) are becoming common. Pfizer’s customers include federal government agencies and institutions, including the VA and its hospitals, and the DoD and its medical facilities. Pfizer colleagues may interact with HCPs who work for these government agencies and institutions and who are employees of the federal government. Interactions with federal employees are governed by the Standards of Ethical Conduct established by the Office of Government Ethics (“Standards of Ethical Conduct”) as well as the local site policies of each institution. In the case of VA employees, your activities are even further restricted by the more specific rules contained in Veterans Health Administration Handbook 1004.07 (“Financial Relationships 73 Rev. 09/12 Page 3 of 25
Page 1 and 2:
Dear Colleagues: Pfizer Inc 235 Eas
Page 3 and 4:
To expand the bookmarks for a chapt
Page 5 and 6:
Orange Guide - Chapter 1: Overview
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Foreign Corrupt Practices Act Orang
Page 17 and 18:
Pfizer’s Corporate Integrity Agre
Page 19 and 20:
Page 21 and 22:
Orange Guide - Chapter 2: Detailing
Page 23 and 24:
Key Points to Ensure Compliance Ora
Page 25 and 26: Orange Guide - Chapter 2: Detailing
Page 27 and 28: Communicating Formulary Status Mail
Page 33 and 34: Hospital Protocols Comparative Clai
Page 39 and 40: Interacting with RMRS Colleagues Or
Page 47 and 48: Detailing at Journal Club Meetings
Page 49 and 50: Orange Guide - Chapter 3: Support o
Page 55 and 56: Medical Education Grants Overview O
Page 57 and 58: International Grant Activity Orange
Page 61 and 62: “Not-for-Profit” Defined Orange
Page 67 and 68: Information on Pfizer’s External
Page 69 and 70: Overview Orange Guide - Chapter 3:
Page 71 and 72: Awards, Scholarships and Fellowship
Page 75: Orange Guide - Chapter 4: Federal E
Page 79 and 80: Orange Guide - Chapter 4: Federal E
Page 81 and 82: Promotional Activities Orange Guide
Page 85 and 86: Speaker Program Meals Part-Time VA
Page 101 and 102: Orange Guide - Chapter 5: Interacti
Page 115 and 116: Discussing Payer Rebates Medical Ac
Page 119 and 120: Orange Guide - Chapter 6: Clinical
Page 127 and 128:
Orange Guide - Chapter 7: P&T Commi
Page 129 and 130:
Page 131 and 132:
Questions From a P&T Committee Memb
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Orange Guide - Chapter 8: Privacy:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Seek Only De-Identified Data Orange
Page 147 and 148:
Consent Forms and Mentorships Orang
Page 149 and 150:
REMEMBER Orange Guide - Chapter 8:
Page 151 and 152:
Proper Use of HCP Prescriber Data O
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Orange Guide - Chapter 9: Speaker P
Page 159 and 160:
Page 161 and 162:
Speaker Selection Scheduling Issues
Page 163 and 164:
Use of Pfizer Approved Speaker Slid
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Providing In-Office Meals to Office
Page 171 and 172:
U.S. HCP Payment Disclosure Policy
Page 173 and 174:
Page 175 and 176:
Closeouts Orange Guide - Chapter 9:
Page 177 and 178:
Page 179 and 180:
Physical Separation of Speaker Prog
Page 181 and 182:
Chapter 10: STARTERS CONTENTS Start
Page 183 and 184:
Page 185 and 186:
Orange Guide - Chapter 10: Starters
Page 187 and 188:
Inclusion of Materials with Starter
Page 189 and 190:
Page 191 and 192:
Distribution of Starters to Colleag
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Orange Guide - Chapter 11: Patient
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
A special note about Medicare Part
Page 207 and 208:
Refer any questions to your team at
Page 209 and 210:
Chapter 12: CONTRACTING Introductio
Page 211 and 212:
Orange Guide - Chapter 12: Contract
Page 213 and 214:
Orange Guide - Chapter 12: Contract
Page 215 and 216:
Page 217 and 218:
Chapter 13: HEALTH SCREENINGS Intro
Page 219 and 220:
Orange Guide - Chapter 13: Health S
Page 221 and 222:
If organized by Pfizer: Orange Guid
Page 223 and 224:
Orange Guide - Chapter 13: Health S
Page 225 and 226:
Orange Guide - Chapter 14: CGC Tool
Page 227 and 228:
Orange Guide - Chapter 14: CGC Tool
Page 229 and 230:
Discussing Pfizer Products While Me
Page 231 and 232:
Orange Guide - Chapter 15: Non-Reba
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Orange Guide - Chapter 16: Consumer
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Providing Food to Consumers at a Di
Page 245 and 246:
Page 247 and 248:
Content of Consumer Slide Decks Att
Page 249 and 250:
Adverse Events Orange Guide - Chapt
Page 251 and 252:
Orange Guide - Chapter 17: State La
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
California Orange Guide - Chapter 1
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Educational Items Orange Guide - Ch
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Orange Guide - Chapter 18: Meals, E
Page 291 and 292:
Page 293 and 294:
Meals to HCPs Orange Guide - Chapte
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Orange Guide - Chapter 19: Sales Ac
Page 313 and 314:
Pricing Considerations Orange Guide
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321:
show all

White Guide and Orange Guide Formatting Project - Pfizer

Create successful ePaper yourself

Delete template?

Save as template?